EMEA-001349-PIP01-12-M03 - paediatric investigation plan
daclizumab
PIPHuman
Biogen Idec Ltd
E-mail: pip.enquiries@biogen.com
Tel. +44 (0)1628 501014
P/0005/2020: EMA decision of 6 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for daclizumab (EMEA-001349-PIP01-12-M03)